Introduction
============

Endothelin-1 (ET-1) produces vasoconstriction by a direct action on vascular smooth muscle cells through stimulation of predominantly ET~A~ receptors, although ET~B~ receptors are involved in some vascular beds ([@b36]; [@b12]). Moreover in the coronary circulation activation of ET-1 receptors has been linked to exaggerated constriction of human coronary artery leading to myocardial ischaemia in coronary artery disease ([@b35]; [@b21]).

ET-1-induced vasoconstriction is mediated almost entirely by influx of Ca^2+^ ions through voltage-independent ion channels (see [@b26]). These data suggest that ET-1 contracts vascular smooth muscle by opening Ca^2+^-permeable non-selective cation channels. Consistent with this notion we demonstrated that ET-1 activates two distinct types of canonical transient receptor potential (TRPC) channels in freshly dispersed rabbit coronary myocytes. At low concentrations (1--10 n[m]{.smallcaps}) ET-1 activates a non-selective cation channel with four subconductance states of between 16 and 68 pS ([@b30]). These responses were mediated mainly by ET~A~ receptors and were mimicked by the diacylglycerol (DAG) analogue, 1-oleoyl-2-acetyl-*sn*-glycerol (OAG) via a protein kinase C (PKC)-independent mechanism. Evidence indicated that this cation channel protein is a heteromeric structure consisting of TRPC3/TRPC7 subunits ([@b30]).

In contrast at higher concentrations (100 n[m]{.smallcaps}) ET-1 evokes a PKC-dependent 2.6 pS Ca^2+^-permeable cation channel which has characteristics of a heteromeric TRPC1/TRPC5/TRPC6 structure (subsequently referred to as TRPC1 channels, [@b33]). With this concentration of ET-1 the TRPC3/TRPC7 conductance is not observed.

In the present study we have investigated the transduction mechanisms linking ET-1 receptors to native TRPC1 ion channels described above in coronary artery myocytes. The results demonstrate that TRPC1 channels may be activated by stimulation of either ET~A~ or ET~B~ receptors using two distinct phosphoinositide signalling pathways involving respectively phosphatidylinositol 3,4,5-trisphosphate (PIP~3~) and phosphatidylinositol 4,5-bisphosphate (PIP~2~). This is the first demonstration that PIP~3~, in addition to PIP~2~, activates native TRPC1 channels.

Methods
=======

Cell isolation
--------------

New Zealand White rabbits (2--3 kg) were killed using [i.v.]{.smallcaps} sodium pentobarbitone (120 mg kg^−1^, in accordance with the UK Animals (Scientific Procedures Act) 1986). Experimental methods were carried out as specified by St George\'s animal welfare committee and according to the policies of *The Journal of Physiology* ([@b13]). Right and left anterior descending coronary arteries were dissected free from fat and connective tissue in physiological salt solution containing (m[m]{.smallcaps}): NaCl (126), KCl (6), glucose (10), Hepes (11), MgCl~2~ (1.2) and CaCl~2~ (1.5), with pH adjusted to 7.2 with 10 [m]{.smallcaps} NaOH. An incision was made along the longitudinal axis of the blood vessels and the exposed endothelium was gently removed using a cotton bud. Enzymatic digestion and smooth muscle cell isolation were subsequently carried using methods previously described ([@b32]).

Electrophysiology
-----------------

Single channel currents were recorded in voltage-clamp mode using cell-attached and inside-out patch configurations ([@b15]) with a HEKA EPC 8 patch-clamp amplifier (HEKA Elektronik, Lambrecht/Pfalz, Germany) at room temperature (20--23°C). Patch pipettes were manufactured from borosilicate glass to produce pipettes with resistances of 6--10 MΩ for isolated patch recording when filled with patch pipette solution. To reduce 'line' noise the recording chamber (vol. *ca* 150--200 μl) was perfused using two 20 ml syringes, one filled with external solution and the other used to drain the chamber, in a 'push and pull' technique. The external solution could be exchanged twice within 30 s. In cell-attached patch recording, the membrane potential was set to ∼0 mV using a high KCl bathing solution (see below). In both cell-attached and inside-out patch recordings, +70 mV was applied to the patch and held at this level except for measuring current--voltage (*I*--*V*) relationships when the applied patch voltage was manually altered between +120 mV and −50 mV. According to convention in the text membrane potential is given with respect to the internal potential and thus, the resting holding potential is referred to as −70 mV.

Single channel currents were initially recorded onto digital audiotape (DAT) using a Sony PCM-R300 digital tape-recorder (BioLogic Science Instruments, Claix, France) at a bandwidth of 5 kHz (HEKA EPC 8 patch-clamp amplifier) and a sample rate of 48 kHz. For off-line analysis, single channel currents were filtered at 100 Hz (see below, −3 db, low pass 8-pole Bessel filter, model LP02, Frequency Devices Inc., Ottawa, IL, USA) and acquired using a Digidata 1322A and pCLAMP 9.0 at a sampling rate of 1 kHz. Data were captured with a Dell Dimension 5150 personal computer.

Single channel current amplitudes were calculated from idealised traces of at least 60 s in duration using the 50% threshold method and analysed using pCLAMP v.9.0 software with events lasting for \<6.664 ms (2 × rise time for a 100 Hz, −3 db, low pass filter) being excluded from analysis. Single channel current amplitude histograms were plotted and fitted with Gaussian curves with the peak of these curves determining the unitary amplitude of the single channel currents. Open probability (*NP*~o~) was calculated automatically using pCLAMP 9. Figure preparation was carried out using Origin 6.0 software (OriginLab Corp., Northampton, MA, USA) where inward single channel openings are shown as downward deflections.

Solutions and drugs
-------------------

In cell-attached patch experiments the membrane potential was set to approximately 0 mV by perfusing cells in a KCl external solution containing (m[m]{.smallcaps}): KCl (126), CaCl~2~ (1.5), Hepes (10) and glucose (11), pH adjusted to 7.2 with 10 [m]{.smallcaps} KOH. Nicardipine (5 μ[m]{.smallcaps}) was also included to prevent smooth muscle cell contraction by blocking Ca^2+^ entry through voltage-dependent Ca^2+^ channels. The bathing solution used in inside-out experiments (intracellular solution) contained (m[m]{.smallcaps}): CsCl (18), caesium aspartate (108), MgCl~2~ (1.2), Hepes (10), glucose (11), BAPTA (1), CaCl~2~ (0.48, free internal Ca^2+^ concentration approximately 100 n[m]{.smallcaps} as calculated using EQCAL software), Na~2~ATP (1) and NaGTP (0.2), pH 7.2 with Tris.

The patch pipette solution used for both cell-attached and inside-out patch recording (extracellular solution) was K^+^ free and contained (m[m]{.smallcaps}): NaCl (126), CaCl~2~ (1.5), Hepes (10), glucose (11), TEA (10), 4-AP (5), iberiotoxin (0.0002), 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS) (0.1), niflumic acid (0.1) and nicardipine (0.005), pH adjusted to 7.2 with NaOH. Under these conditions voltage-dependent Ca^2+^ currents, K^+^ currents, swell-activated Cl^−^ currents and Ca^2+^-activated Cl^−^ conductances are abolished and non-selective cation currents could be recorded in isolation.

Anti-TRPC1 (which detects TRPC1 proteins with a predicted molecular mass of ∼100 kDa) and anti-PIP~2~ antibodies (which detect liposome complex of PIP~2~ molecules with a predicted molecular mass of ∼75 kDa, see manufacturer\'s data sheet and [@b14]) were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) and alomone labs (Israel), anti-PIP~3~ antibodies were from MBL (Japan) and anti-β-actin antibodies were from Sigma (UK). Pre-incubation of anti-TRPC1 antibodies with its antigenic peptide was carried out in a 1: 2 ratio for at least 2 h in control experiments. Unless otherwise stated all other drugs were purchased from Calbiochem (UK), Sigma (UK) or Tocris (UK) and agents were dissolved in distilled H~2~O or DMSO (0.1%). DMSO alone had no effect on channel activity. The values are the mean of *n* cells ±[s.e.m.]{.smallcaps} Statistical analysis was carried out using paired (comparing effects of agents on the same cell) or unpaired (comparing effects of agents between cells) Students'*t* test with the level of significance set at *P* \< 0.05.

Immunoprecipitation and Western blotting
----------------------------------------

Dissected tissues were flash frozen and stored in 10 m[m]{.smallcaps} TRIS-HCl (pH 7.4) at −80°C for subsequent use. Tissues were defrosted and mechanically disrupted with an Ultraturrax homogeniser and further disrupted by sonication on ice for at least 2 h. Tissues were subsequently centrifuged at 25 000 *g* for 30 min at 4°C and the supernatant was discarded. The total cell lysate (TCL) was then collected by centrifugation at 11 200 *g* for 10 min in 10 mg ml^−1^ RIPA lysis buffer (Santa Cruz Biotechnology), supplemented with protease inhibitors. Protein content was quantified using the Bio-Rad protein dye reagent (Bradford method). TCL was retained on ice for subsequent experimental procedures including dot-blots and immunoprecipitation. Dot-blots were carried out by 'spotting' 2--5 μl of TCL on prepared immobilon-p polyvinylidene difluoride (PVDF) membranes. Membranes were allowed to dry prior to detection using conventional Western blotting techniques (see later). The immunoprecipitation protocol was carried out using the Millipore Catch and Release® kit, where spin columns were loaded with 500 μg of TCL and 2--6 μg of antibody and immunoprecipitated for 2 h at room temperature.

Immunoprecipitated samples were eluted with Laemmli sample buffer and incubated at 60°C for 5 min. One-dimensional protein gel electrophoresis was performed in 4--12% Bis-Tris Gels in a Novex mini-gel system (Invitrogen) with 10--20 μg of total protein loaded in each lane. Separated proteins were transferred onto PVDF membranes using the Invitrogen iBlot apparatus. Western blotting was subsequently carried out on membranes which were incubated with the appropriate primary antibody for 2 h at room temperature. Where possible, alternative antibodies raised against different epitopes were used for immunoprecipitation and Western blot analysis. Following antibody removal membranes were washed for 2 h with milk/phosphate-buffered saline with Tween 20 (PBST) and were subsequently incubated with horseradish peroxidase-conjugated secondary antibody diluted 1: 1000--5000 in milk/PBST. Membranes were then washed 3 times for 15 min in PBST, followed by a final wash in PBS before being treated with ECL chemiluminescence reagents (Pierce Biotechnology, Inc., Rockford, IL, USA) for 1 min and exposed to photographic films. Data shown represents *n* values of at least three separate experiments.

Results
=======

Stimulation of ET~A~ and ET~B~ receptors activate 2--3 pS cation channel currents in rabbit coronary artery myocytes
--------------------------------------------------------------------------------------------------------------------

In initial experiments we investigated the identity of the ET-1 receptor subtype involved in activating native 2--3 pS cation channel currents. For these experiments 100 n[m]{.smallcaps} ET-1 was used since at these concentrations ET-1 does not activate the TRPC3/C7 conductance expressed in this preparation (see [@b30] and Introduction) and the 2--3 pS conductance is recorded in isolation. Both ET~A~ and ET~B~ G-protein-coupled receptors are expressed in vascular smooth muscle (see [@b26]) and therefore we studied the effect of selective concentrations of ET~A~ and ET~B~ receptor antagonists, respectively BQ-123 and BQ-788 ([@b11]), on ET-1-induced native 2--3 pS channel activity in cell-attached patches from freshly dispersed coronary artery myocytes.

[Figure 1*A*, *E* and *F*](#fig01){ref-type="fig"} shows that bath application of 100 n[m]{.smallcaps} ET-1 activated cation channel activity at −70 mV which had a mean peak open probability (*NP*~o~) of 0.25 ± 0.07 (*n*= 10) and was composed of channel openings with a unitary conductance of 2.6 pS and a reversal potential (*E*~r~) of about 0 mV. These responses were seen in approximately 90% of patches tested. [Figure 1*Ab*](#fig01){ref-type="fig"} illustrates that the channel current amplitude histogram of ET-1-evoked channel activity shown in [Fig. 1*Aa*](#fig01){ref-type="fig"} could be fitted by the sum of four Gaussian curves representing one closed and three open levels of the same conductance, i.e. there were at least three channels in the patch. [Figure 1*B* and *F*](#fig01){ref-type="fig"} shows that pre-treatment with the ET~A~ receptor antagonist 100 n[m]{.smallcaps} BQ-123 for 5 min had no effect on ET-1-induced channel activity (*n*= 10). In addition, [Fig. 1*C* and *F*](#fig01){ref-type="fig"} shows that pre-treatment with the ET~B~ receptor antagonist 100 n[m]{.smallcaps} BQ-788 for 5 min also had no effect on ET-1-evoked channel activity (*n*= 10). [Figure 1*E*](#fig01){ref-type="fig"} shows that ET-1 activated the same 2.6 pS channel currents in the presence of either BQ-123 or BQ-788 and in the absence of receptor antagonists. However, [Fig. 1*D* and *F*](#fig01){ref-type="fig"} illustrates that that pre-treatment with co-application of both 100 n[m]{.smallcaps} BQ-123 and 100 n[m]{.smallcaps} BQ-788 for 5 min almost completely abolished ET-1-induced channel activity (*n*= 8, *P* \< 0.001).

![Stimulation of ET~A~ and ET~B~ receptors activates 2--3 pS cation channel currents in cell-attached patches from freshly dispersed coronary artery myocytes\
*Aa*, bath application of 100 n[m]{.smallcaps} ET-1 induced cation channel activity at an applied patch voltage of +70 mV. According to convention we will refer to this as −70 mV membrane potential throughout the text (see Methods). *Ab*, amplitude histogram of channel currents shown in *Aa* could be fitted with the sum of four Gaussian curves indicating 1 closed and 3 multiple open levels inferring that the patch contained at least 3 channels. *B* and *C*, ET-1 evoked cation channel activity in the presence of respectively either the ET~A~ receptor antagonist 100 n[m]{.smallcaps} BQ-123 or the ET~B~ receptor antagonist 100 n[m]{.smallcaps} BQ-788. *D* and *F*, ET-1-induced cation channel activity was blocked in the presence of a mixture of 100 n[m]{.smallcaps} BQ-123 and 100 nv BQ-788 at −70 mV. *E*, *I*--*V* relationship of cation channel currents evoked by ET-1 (open circles), ET-1 in the presence of BQ-123 (open squares) and ET-1 in the presence of BQ-788 (filled squares) showing that they all had a unitary conductance of 2.6 pS and *E*~r~ of about 0 mV. Each point represents at least *n*= 6. *F*, mean data showing neither BQ-123 nor BQ-788 inhibited ET-1-evoked channel activity when applied separately. However when the antagonists were added together ET-1-evoked cation channel activity was abolished. Each value is the mean of 10 patches.](tjp0587-5361-f1){#fig01}

These data showing that both ET~A~ and ET~B~ receptor antagonists must be present to block channel activity by ET-1 indicate that stimulation of both ET~A~ and ET~B~ receptors can lead to channel opening.

Stimulation of ET~A~ and ET~B~ receptors activates TRPC1 channel currents through a PKC-dependent mechanism
-----------------------------------------------------------------------------------------------------------

Previously we have shown that ET-1 and agents that deplete internal Ca^2+^ stores, cyclopiazonic acid (CPA) and BAPTA-AM, evoke native 2.6 pS TRPC1 channel currents in coronary artery myocytes which are inhibited by PKC inhibitors ([@b33]; [@b8]). Therefore we investigated the role of PKC and TRPC1 subunits in mediating both ET~A~ and ET~B~ receptor-mediated channel activity. In these experiments we bath applied ET-1 in the presence of either BQ-788 or BQ-123 to evoke respectively ET~A~ or ET~B~ receptor-coupled pathways in cell-attached patches.

[Figure 2*A*](#fig02){ref-type="fig"} shows that the mean *NP*~o~ of ET~A~ receptor-mediated channel activity, activated by 100 n[m]{.smallcaps} ET-1 in the presence of 100 n[m]{.smallcaps} BQ-788, was significantly reduced from 0.37 ± 0.04 to 0.06 ± 0.01 (83 ± 5% inhibition, *n*= 6, *P* \< 0.01) by the PKC inhibitor chelerythrine (3 μ[m]{.smallcaps}). [Figure 2*B*](#fig02){ref-type="fig"} shows that the mean *NP*~o~ of ET~B~ receptor-mediated channel activity, activated by 100 n[m]{.smallcaps} ET-1 in the presence of 100 n[m]{.smallcaps} BQ-123, was also significantly inhibited from 0.31 ± 0.08 to 0.05 ± 0.02 (84 ± 3% inhibition, *n*= 7, *P* \< 0.01) by 3 μ[m]{.smallcaps} chelerythrine.

![Stimulation of ET~A~ and ET~B~ receptors activates native TRPC1 channel currents via a PKC-dependent mechanism\
*A* and *B*, stimulation of ET~A~ (100 n[m]{.smallcaps} BQ-788 present) or ET~B~ receptors (100 n[m]{.smallcaps} BQ-123 present) with 100 n[m]{.smallcaps} ET-1 evoked channel activity that was inhibited by co-application of 3 μ[m]{.smallcaps} chelerythrine in cell-attached patches held at −70 mV. *C* and *D*, stimulation of respectively ET~A~ and ET~B~ receptors evoked channel activity initially induced in cell-attached patches which was inhibited by application of 1: 200 dilution of anti-TRPC1 antibodies following excision of patches into the inside-out configuration (i/o). *E* and *F*, following pre-incubation of anti-TRPC1 antibodies (1: 200) with its antigenic peptide (1: 100, AgP) bath application of the complex had no effect on ET~A~ receptor-mediated or ET~B~ receptor-mediated channel activity.](tjp0587-5361-f2){#fig02}

[Figure 2*C*](#fig02){ref-type="fig"} illustrates that ET~A~ receptor-mediated channel activity in cell-attached patches was maintained following excision into the inside-out configuration and that bath application of anti-TRPC1 antibodies to the cytosolic surface of these inside-out patches significantly reduced mean *NP*~o~ of ET~A~ receptor-mediated activity from 0.19 ± 0.03 to 0.01 ± 0.01 (95 ± 5% inhibition, *n*= 5, *P* \< 0.01). Moreover [Fig. 2*D*](#fig02){ref-type="fig"} shows that anti-TRPC1 antibodies also significantly inhibited the mean *NP*~o~ of ET~B~ receptor-mediated channel activity from 0.22 ± 0.08 to 0.03 ± 0.02 (87 ± 8% inhibition, *n*= 5, *P* \< 0.01). In control experiments, [Fig. 2*E* and *F*](#fig02){ref-type="fig"} show that following pre-incubation with their antigenic peptide, anti-TRPC1 antibodies had no effect on ET~A~ receptor-mediated or ET~B~ receptor-mediated channel activity (*n*= 4 for each). Channel activity often recovered, at least partially, following washout of anti-TRPC1 antibodies indicating some degree of reversibility in the conditions used.

These data show that stimulation of both ET~A~ and ET~B~ receptors activates TRPC1 channel currents through a PKC-dependent mechanism in coronary artery myocytes.

Distinct signalling pathways mediate ET~A~ and ET~B~ receptor stimulation of TRPC1 channel activity
---------------------------------------------------------------------------------------------------

In the next series of experiments we investigated the signalling pathways linking ET~A~ and ET~B~ receptors to PKC-mediated opening of TRPC1 channels. ET~A~ and ET~B~ G-protein-coupled receptors can be linked to different phospholipases that generate the endogenous PKC activator diacylglycerol (DAG, [@b19]). Therefore we investigated the effect of biochemically characterised pharmacological inhibitors of endogenous phospholipases on ET~A~ and ET~B~ receptor-mediated TRPC1 channel activity in cell-attached patches.

[Figure 3*A*](#fig03){ref-type="fig"} shows that the phosphoinositol-phospholipase C (PI-PLC) inhibitor U73122 (2 μ[m]{.smallcaps}) significantly inhibited the mean *NP*~o~ of ET~B~ receptor-mediated TRPC1 channel activity from 0.26 ± 0.05 to 0.04 ± 0.02 (89 ± 4% inhibition, *n*= 7, *P* \< 0.01) whereas [Fig. 3*B*](#fig03){ref-type="fig"} demonstrates that this PI-PLC inhibitor had no effect on ET~A~ receptor-mediated TRPC1 channel activity (control mean *NP*~o~ was 0.21 ± 0.06 and 0.18 ± 0.05 in U73122, *n*= 7). In addition, 2 μ[m]{.smallcaps} U73343, an inactive analogue of U73122, had no effect on ET~B~ receptor-mediated TRPC1 channel activity (*n*= 4, data not shown).

![Stimulation of ET~B~, but not ET~A~, receptors activates TRPC1 channel currents via a PLC-mediated transduction pathway in cell-attached patches\
*A*, ET~B~ receptor-mediated TRPC1 channel activity was inhibited by co-application of 2 μ[m]{.smallcaps} U73122 at −70 mV. *B*, ET~A~ receptor-mediated TRPC1 channel activity was unaffected by co-application of 2 μ[m]{.smallcaps} U73122. *C*, mean data showing that ET~A~ receptor-mediated TRPC1 channel activity (ET-1-evoked *NP*~o~ in the presence of 100 n[m]{.smallcaps} BQ-788) at −70 mV was also unaffected by co-application of inhibitors against different phospholipases and Rho kinase (see text for details).](tjp0587-5361-f3){#fig03}

The above studies indicate that a PI-PLC-mediated mechanism couples ET~B~ receptors to TRPC1 channel stimulation but is unlikely to be involved in activating native TRPC1 channels through stimulation of ET~A~ receptors. Therefore we investigated the effects of several established inhibitors of other phospholipases that may be involved in ET~A~ receptor-mediated activation of TRPC1 channel currents. [Figure 3*C*](#fig03){ref-type="fig"} shows that pharmacological inhibitors of phosphatidylcholine-PLC (PC-PLC, 100 μ[m]{.smallcaps} D-609, *n*= 5), cytosolic and Ca^2+^-dependent and -independent forms of phospholipase A~2~ (PLA~2~, 100 μ[m]{.smallcaps} AACOCF~3~, *n*= 4 and 100 μ[m]{.smallcaps} PACOCF~3~, *n*= 4) and phospholipase D (PLD, 100 μ[m]{.smallcaps} C2-ceramide, *n*= 6) had no effect on ET~A~ receptor-mediated TRPC1 channel activity. Stimulation of ET~A~ receptors has also been shown to activate Rho kinase ([@b19]) but [Fig. 3*C*](#fig03){ref-type="fig"} shows that the Rho kinase inhibitors HA-110 (5 μ[m]{.smallcaps}, *n*= 5) and Y27632 (1 μ[m]{.smallcaps}, *n*= 5) had no effect on ET~A~ receptor-mediated TRPC1 channel activity. These data suggest that PC-PLC, PLA~2~, PLD and Rho kinase are also not involved in TRPC1 channel activation initiated by ET~A~ receptor stimulation.

Previous studies have shown that stimulation of ET~A~ receptors can activate phosphoinositol-3-kinase (PI-3-kinase), which phosphorylates PIP~2~ to form PIP~3~, with the latter phospholipid capable of stimulating PKC activity (see review by [@b19]). Therefore we investigated the role of a PI-3-kinase-mediated mechanism on ET~A~ and ET~B~ receptor-mediated TRPC1 channel activity in cell-attached patches using selective concentrations of wortmannin and a structurally different compound, PI-828, which both inhibit PI-3-kinase. [Figure 4*A*](#fig04){ref-type="fig"} shows that 50 n[m]{.smallcaps} wortmannin significantly reduced mean *NP*~o~ of ET~A~ receptor-mediated TRPC1 channel activity from 0.23 ± 0.06 to 0.02 ± 0.01 (94 ± 4% inhibition, *n*= 6, *P* \< 0.01). In addition [Fig. 4*B*](#fig04){ref-type="fig"} shows that 3 μ[m]{.smallcaps} PI-828 also significantly attenuated mean *NP*~o~ of ET~A~ receptor-mediated TRPC1 channel activity from 0.14 ± 0.04 to 0.02 ± 0.01 (85 ± 5% inhibition, *n*= 5, *P* \< 0.01). Importantly, [Fig. 4*C* and *D*](#fig04){ref-type="fig"} illustrates that 50 n[m]{.smallcaps} wortmannin (control mean *NP*~o~ of 0.18 ± 0.06 and 0.18 ± 0.07 in wortmannin, *n*= 6) and 3 μ[m]{.smallcaps} PI-828 (control mean *NP*~o~ of 0.31 ± 0.11 and 0.24 ± 0.08 in PI-828, *n*= 6) had no effect on ET~B~ receptor-mediated TRPC1 channel activity indicating that these reagents do not have direct non-specific effects on TRPC1 channel currents.

![Stimulation of ET~A~ receptors activates TRPC1 channel currents via a PI-3-kinase-mediated pathway in cell-attached patches\
*A* and *B* show that ET~A~ receptor-mediated TRPC1 channel activity was inhibited by co-application of 50 n[m]{.smallcaps} wortmannin or 3 μ[m]{.smallcaps} PI-828, whereas *C* and *D* show that these compounds had no effect on ET~B~ receptor-mediated TRPC1 channel activity.](tjp0587-5361-f4){#fig04}

These results provide evidence that stimulation of ET~A~ and ET~B~ receptors evokes TRPC1 channel activity via different signal transduction mechanisms. Stimulation of ET~A~ receptors is coupled to TRPC1 channels via a PI-3-kinase-dependent pathway whereas a PI-PLC-dependent pathway links ET~B~ receptor-mediated TRPC1 channel opening, and both these pathways are likely to induce TRPC1 channel activity through a PKC-dependent mechanism.

Involvement of PIP~3~ in ET~A~ receptor-mediated activation of TRPC1 channel currents
-------------------------------------------------------------------------------------

The above results suggest that generation of PIP~3~ produced from the action of PI-3-kinase on PIP~2~ is required for ET~A~ receptor-mediated TRPC1 channel stimulation. Consequently we investigated if exogenous PIP~3~ directly activates TRPC1 channel currents in coronary artery myocytes.

[Figure 5*A* and *B*](#fig05){ref-type="fig"} shows that bath application of 3 μ[m]{.smallcaps} diC8-PIP~3~, a water soluble form of PIP~3~, to the cytosolic surface of inside-out patches activated cation channel activity with a mean *NP*~o~ of 0.32 ± 0.06 (*n*= 11) and a unitary conductance of 2.6 pS with an *E*~r~ of about 0 mV. The threshold concentration of diC8-PIP~3~ was approximately 1 μ[m]{.smallcaps} and maximum channel activation was obtained with 10--20 μ[m]{.smallcaps} diC8-PIP~3~ (data not shown). [Figure 5*C* and *D*](#fig05){ref-type="fig"} also illustrates that mean *NP*~o~ of diC8-PIP~3~-evoked channel activity in inside-out patches was significantly inhibited from 0.21 ± 0.09 to 0.02 ± 0.02 (94 ± 4% inhibition, *n*= 5, *P* \< 0.01) by co-application with 3 μ[m]{.smallcaps} chelerythrine and from 0.28 ± 0.05 to 0.03 ± 0.02 (84 ± 7% inhibition, *n*= 5, *P* \< 0.01) with anti-TRPC1 antibodies.

![PIP~3~ activates TRPC1 channel currents via a PKC-dependent mechanism\
*A*, bath application of 3 μ[m]{.smallcaps} diC8-PIP~3~ activates cation channel activity in an inside-out patch at −70 mV. *B*, current--voltage relation of diC8-PIP~3~-evoked cation channel activity yielded a unitary conductance of 2.6 pS and an *E*~r~ of about 0 mV. Each point was at least *n*= 4. *C* and *D*, respectively 3 μ[m]{.smallcaps} chelerythrine and 1: 200 dilution of anti-TRPC1 antibodies inhibited diC8-PIP~3~-induced channel activity in inside-out patches at −70 mV. *E* and *F*, co-application of 1: 200 dilution of anti-PIP~3~ antibodies reduced ET~A~ receptor-mediated TRPC1 channel activity (*E*) but had no effect on ET~B~ receptor-mediated TRPC1 channel activity (*F*).](tjp0587-5361-f5){#fig05}

The role of endogenous PIP~3~ in ET~A~ receptor-mediated stimulation of TRPC1 channel activity was investigated using an anti-PIP~3~ antibody. [Figure 5*E*](#fig05){ref-type="fig"} shows that the mean *NP*~o~ of ET~A~ receptor-mediated TRPC1 channel stimulation, initially activated in cell-attached patches in the presence of the ET~B~ receptor antagonist BQ-788, was significantly reduced from 0.25 ± 0.07 to 0.01 ± 0.01 (97 ± 1% inhibition, *n*= 6, *P* \< 0.01) by bath application of an anti-PIP~3~ antibody to the cytosolic surface of the patches. In contrast, [Fig. 5*F*](#fig05){ref-type="fig"} illustrates that an anti-PIP~3~ antibody had no effect on ET~B~ receptor-mediated TRPC1 channel activity (control mean *NP*~o~ from 0.48 ± 0.08 to 0.51 ± 0.11 in anti-PIP~3~ antibody, *n*= 6).

These data clearly show that exogenous PIP~3~ and ET-1 activate the same PKC-dependent TRPC1 channel currents and also indicate that endogenous PIP~3~ mediates activation of TRPC1 channel currents by ET~A~ receptor stimulation.

Involvement of PIP~2~ in ET~B~ receptor-mediated activation of TRPC1 channel currents
-------------------------------------------------------------------------------------

The above results indicate that ET~B~ receptor-mediated TRPC1 channel activity is coupled to a PI-PLC pathway and to stimulation of PKC (see [Figs 2](#fig02){ref-type="fig"} and [3](#fig03){ref-type="fig"}). Previous work suggests that this biochemical cascade is likely to involve generation of DAG, through hydrolysis of PIP~2~ by PI-PLC, since 1-oleoyl-2-acetyl-*sn*-glycerol (OAG), a cell-permeant DAG analogue, activates TRPC1 channel activity through a PKC-dependent mechanism in rabbit mesenteric artery, portal vein and also coronary artery (see [@b2]; [@b32], [@b33]). Moreover, our recent findings extended this hypothesis by proposing an obligatory role for PIP~2~ in PKC-dependent activation of TRPC1 channels in portal vein smooth muscle cells ([@b34]) and therefore we investigated the effects of PIP~2~ in coronary artery myocytes.

Bath application of 10 μ[m]{.smallcaps} diC8-PIP~2~ to inside-out patches induced cation channel activity which had a mean *NP*~o~ of 0.34 ± 0.11 at −70 mV (*n*= 11) and a unitary conductance of 2.6 pS and an *E*~r~ of about 0 mV ([Fig. 6*Aa* and *b*](#fig06){ref-type="fig"}). In addition, the mean *NP*~o~ of diC8-PIP~2~-evoked channel activity was significantly reduced by co-application of anti-TRPC1 antibodies (from 0.24 ± 0.08 to 0.02 ± 0.01, 88 ± 6% inhibition, *n*= 5, *P* \< 0.01, [Fig. 6*B*](#fig06){ref-type="fig"}) and by 3 μ[m]{.smallcaps} chelerythrine (from 0.31 ± 0.08 to 0.05 ± 0.03, 97 ± 6% inhibition, *n*= 6, *P* \< 0.01, [Fig. 6*C*](#fig06){ref-type="fig"}). These data provide evidence that exogenous PIP~2~ activates TRPC1 channel currents via a PKC-dependent mechanism.

![Obligatory role of PIP~2~ in mediating OAG-induced TRPC1 channel activity via a PKC-dependent mechanism\
*Aa* and *b*, bath application of 10 μ[m]{.smallcaps} diC8-PIP~2~ activates cation channel activity in inside-out patches at −70 mV which has a unitary conductance of 2.6 pS and a *E*~r~ of about 0 mV. *B* and *C*, diC8-PIP~2~-evoked channel activity is inhibited by 1: 200 anti-TRPC1 antibodies (*B*) and also by 3 μ[m]{.smallcaps} chelerythrine (*C*). *D* and *E*, OAG-induced channel activity is inhibited by 1: 200 anti-TRPC1 antibodies (*D*) and also by 1: 200 anti-PIP~2~ antibodies (*E*) in inside-out patches held at −70 mV. *F*, pre-treatment with 20 μ[m]{.smallcaps} wortmannin for 30 min prevented activation of TRPC1 activity by OAG in a cell-attached patches at −70 mV.](tjp0587-5361-f6){#fig06}

OAG-evoked channel activity was significantly inhibited by anti-TRPC1 antibodies ([Fig. 6*D*](#fig06){ref-type="fig"}, mean *NP*~o~ from 0.23 ± 0.08 to 0.03 ± 0.01, 87 ± 1% inhibition, *n*= 4, *P* \< 0.01) and by anti-PIP~2~ antibodies ([Fig. 6*E*](#fig06){ref-type="fig"}, mean *NP*~o~ from 0.32 ± 0.06 to 0.01 ± 0.01, 97 ± 1% inhibition, *n*= 6, *P* \< 0.01) in inside-out patches. [Figure 6*F*](#fig06){ref-type="fig"} also shows that when tissues were pre-treated with 20 μ[m]{.smallcaps} wortmannin for 30 min to deplete tissue PIP~2~ levels (see [Fig. 7](#fig07){ref-type="fig"}) OAG did not evoke TRPC1 channel activity in cell-attached patches (mean *NP*~o~ of 0.01 ± 0.01, *n*= 6). These results suggest that endogenous PIP~2~ has an obligatory role for OAG-evoked TRPC1 channel activation.

![PIP~3~ activation of TRPC1 channel activity is independent of PIP~2~\
*A*, diC8-PIP~3~-evoked TRPC1 channel activity in inside-out patches held at −70 mV was not inhibited by pre-treatment with 20 μ[m]{.smallcaps} wortmannin for 30 min. *B*, 1: 200 anti-PIP~2~ antibodies did not inhibit diC8-PIP~3~-mediated channel activation. *Ca*, co-immunoprecipitation experiment showing association between PIP~2~ and TRPC1 proteins at rest (Con) after immunoprecipitation with anti-TRPC1 antibodies and blotting with anti-PIP~2~ antibodies which was reduced following pre-treatment with 20 μ[m]{.smallcaps} wortmannin (Wort). *Cb*, upper panel shows co-immunoprecipitation experiment following immunoprecipitation with anti-PIP~2~ antibodies and blotting with anti-TRPC1 antibodies illustrating that PIP~2~ association with TRPC1 proteins is unaltered following pre-treatment with 100 n[m]{.smallcaps} ET-1 and stimulation of ET~A~ (100 n[m]{.smallcaps} ET-1 + 100 n[m]{.smallcaps} BQ-788) or ET~B~ (100 n[m]{.smallcaps} ET-1 + 100 n[m]{.smallcaps} BQ-123) receptors. Lower panel shows a Western blot in which following preincubation with its antigenic peptide (AgP), detection of TRPC1 protein with anti-TRPC1 antibodies was reduced. *Ca* and *b* also show that wortmannin and antigenic peptide had no effect on expression of β-actin proteins. *D*, dot-blot showing the presence of PIP~2~ but not PIP~3~ levels in tissue lysates at rest and the reduction of PIP~2~ levels and increase of PIP~3~ levels following stimulation of ET~A~ receptors.](tjp0587-5361-f7){#fig07}

These studies demonstrate that stimulation of ET~B~ receptors induces TRPC1 channel activation through stimulation of PI-PLC to generate DAG which activates PKC leading to channel opening through a mechanism involving endogenous PIP~2~.

PIP~3~ evokes TRPC1 channel activity independently of PIP~2~
------------------------------------------------------------

The present work shows that stimulation of ET~A~ receptors activates TRPC1 activity through a PI-3-kinase-mediated pathway involving PIP~3~ (see [Figs 4](#fig04){ref-type="fig"} and [5](#fig05){ref-type="fig"}). Moreover we demonstrate that exogenous diC8-PIP~3~ evokes PKC-dependent TRPC1 channel activity (see [Fig. 5](#fig05){ref-type="fig"}). In contrast, our data indicate that activation of TRPC1 channels by stimulation of ET~B~ receptors involves a permissive role for PIP~2~. In a previous report we stated that PIP~2~ had an obligatory role for TRPC1 channel activation in rabbit portal vein myocytes ([@b34]). Therefore we investigated whether endogenous PIP~2~ was necessary for activation of TRPC1 channels by PIP~3~ in coronary artery smooth muscle cells.

[Figure 7*A*](#fig07){ref-type="fig"} shows that following pre-treatment of myocytes with 20 μ[m]{.smallcaps} wortmannin for 30 min to deplete PIP~2~ levels (see [Fig. 5*Ca*](#fig05){ref-type="fig"}) bath application of 3 μ[m]{.smallcaps} diC8-PIP~3~ activated TRPC1 channel activity with a mean peak *NP*~o~ value of 0.31 ± 0.05 (*n*= 6) in inside-out patches, which is similar to control values of channel activity induced by 3 μ[m]{.smallcaps} PIP~3~ in the absence of wortmannin (see above and [Fig. 7*Aa*](#fig07){ref-type="fig"}). [Figure 7*B*](#fig07){ref-type="fig"} shows that anti-PIP~2~ antibodies had no effect on PIP~3~-induced TRPC1 channel activity in inside-out patches (control mean *NP*~o~ of 0.23 ± 0.06 and 0.24 ± 0.08 in the presence of anti-PIP~2~ antibodies, *n*= 6). Both of these procedures blocked OAG-evoked TRPC1 channel activity (cf. [Fig. 6*E* and *F*](#fig06){ref-type="fig"}). In other experiments the anti-PIP~2~ antibody reduced TRPC1 channel activation by both ET~A~ and ET~B~ receptor stimulation (data not shown). This is predictable since PIP~2~ acts as a substrate for PIP~3~ generated by PI-3-kinase (ET~A~ pathway) and DAG produced by PI-PLC (ET~B~ pathway).

Therefore with regard to direct TRPC1 channel activation endogenous PIP~2~ is not obligatory for TRPC1 channel activation by PIP~3~ (ET~A~ receptor pathway) but is necessary for OAG (DAG)-induced (ET~B~ receptor pathway) TRPC1 channel stimulation.

To further investigate the role of PIP~2~ and PIP~3~ in mediating ET-1-induced TRPC1 channel activation we carried out co-immunoprecipitation and dot-blot studies. [Figure 7*Ca*](#fig07){ref-type="fig"} illustrates a co-immunoprecipitation experiment which shows that at rest PIP~2~ is associated with TRPC1 proteins in coronary artery when tissue lysates were immunoprecipitated with anti-TRPC1 antibodies and then blotted with anti-PIP~2~ antibodies to detect a predicted band of ∼75 kDa (see Methods). In addition [Fig. 7*Ca*](#fig07){ref-type="fig"} shows that pre-treatment of coronary arteries with 20 μ[m]{.smallcaps} wortmannin for 30 min reduced PIP~2~ association with TRPC1 proteins whereas total β-actin levels were not altered. The upper panel in [Fig. 7*Cb*](#fig07){ref-type="fig"} shows that stimulation of ET~A~ or ET~B~ receptors did not alter PIP~2~ association with TRPC1 proteins following immunoprecipitation with anti-PIP~2~ antibodies and blotting with anti-TRPC1 antibodies to detect a predicted band of ∼100 kDa (see Methods). The middle panel shows a control experiment in which pre-incubation of the anti-TRPC1 antibody with its antigenic peptide (AgP) reduced the detection of the predicted band for TRPC1 proteins on a Western blot. The lower panel shows that the antigenic peptide had no effect on the expression of β-actin.

It was not possible to detect total PIP~3~ levels using Western blotting or association between PIP~3~ and TRPC1 proteins using co-immunoprecipitation at rest or after stimulation of ET~A~ and ET~B~ receptors. This is probably due to resting and receptor-mediated generation of PIP~3~ levels being too small to resolve with the limited amounts of available coronary artery tissue. Therefore we measured PIP~3~ and PIP~2~ levels using tissue lysate and dot-blot techniques with their respective antibodies. [Figure 7*D*](#fig07){ref-type="fig"} illustrates that at rest total cell lysates from coronary arteries contained detectable PIP~2~ but not PIP~3~ whereas upon stimulation of ET~A~ receptors (ET-1 in the presence of BQ-788) the levels of PIP~2~ were reduced and generation of PIP~3~ was detected whereas levels of β-actin were unaffected.

These data provide novel evidence that PIP~3~ can activate TRPC1 channels independently of PIP~2~ in coronary artery myocytes.

Discussion
==========

The present work provides the first evidence that stimulation of ET~A~ and ET~B~ receptors by ET-1 activates native TRPC1 channel currents in freshly dispersed coronary artery myocytes by two distinct parallel phosphoinositide signalling pathways. Evidence is provided to show that stimulation of ET~A~ receptors evokes TRPC1 channel currents through PI-3-kinase-mediated generation of PIP~3~ which leads to opening of TRPC1 channels, possibly by a direct action. In contrast ET~B~ receptors are coupled to PI-PLC and production of DAG leading to PIP~2~-mediated TRPC1 channel activation. Moreover it appears that PKC is involved in activation of TRPC1 channel currents by both PIP~3~ and PIP~2~. Previously we have shown a permissive role for PIP~2~ in activating TRPC1 channels in rabbit portal vein myocytes ([@b34]) but this is the first demonstration that PIP~3~ also activates native TRPC1 channel currents. Furthermore, to our knowledge, this is the first evidence that PI-3-kinase may be involved in activation of TRPC1 channel. Importantly, this pathway involving PI-3-kinase-mediated generation of PIP~3~ represents a novel activation mechanism of TRPC channels.

ET~A~ receptor transduction mechanism and activation of TRPC1 channel currents
------------------------------------------------------------------------------

ET~A~ receptor-mediated stimulation of TRPC1 channel activity is blocked by PI-3-kinase inhibitors and by an anti-PIP~3~ antibody which did not inhibit TRPC1 channel activation induced by ET~B~ receptor stimulation. Moreover exogenous PIP~3~ applied to inside-out patches evoked cation channel currents with identical properties to those stimulated by ET-1, i.e. native TRPC1 channels. Importantly, PIP~3~-induced TRPC1 channel activation did not require endogenous PIP~2~ since PIP~3~ readily activated TRPC1 channel currents in tissues pre-treated with high concentrations of wortmannin, which reduced association of PIP~2~ with TRPC1. Moreover an anti-PIP~2~ antibody which blocked responses to OAG did not inhibit PIP~3~-evoked TRPC1 channel activity. Thus generation of PIP~3~ by stimulation of ET~A~ receptors activates TRPC1 channels with PIP~3~ possibly being the activating ligand, which represents a novel mechanism of ion channel activation.

Stimulation of ET~A~ receptors expressed in Chinese hamster ovary cells has been shown to increase PI-3-kinase activity and PIP~3~ formation which was inhibited by low concentrations of wortmannin ([@b37]). Our data also show that ET~A~ receptor stimulation increases PIP~3~ production. In vascular smooth muscle ET-1 receptor stimulation leads to activation of several signalling pathways including PI-3-kinase (see review by [@b9]) and this mechanism is involved in vasoconstriction ([@b20]). Previously PIP~3~ has been shown to bind to expressed TRPC1 proteins ([@b22]) although another study suggested that PIP~3~ did not activate expressed TRPC1 channels ([@b38]). However in the same work it was shown that PIP~3~ produces marked stimulation of TRPC6 channel activity ([@b38]). Previously we indicated that the 2.6 pS ET-1-induced conductance in coronary artery myocytes may be a heteromeric channel consisting of TRPC1, TRPC5 and TRPC6 subunits ([@b33]). Therefore it is possible that the heteromeric structure of native TRPC1 channels is more sensitive to PIP~3~ then heterologously expressed TRPC1 proteins or that PIP~3~ binds to proposed TRPC5 or TRPC6 subunits of the native conductance in coronary artery myocytes.

The present work does not reveal how ET~A~ receptors are linked to PI-3-kinase in coronary arteries but in other systems it has been shown, and is generally accepted, that G~βγ~ subunits activate PI-3-kinase (see [@b10]; [@b40]).

ET~B~ receptor transduction mechanism and activation of TRPC1 channel currents
------------------------------------------------------------------------------

The present work shows that ET~B~ receptor-induced stimulation of TRPC1 channel activity was markedly inhibited by the PI-PLC inhibitor U73122, which did not effect ET~A~ receptor-mediated activation of TRPC1 channel activity. In addition OAG, an analogue of DAG which is a product of PI-PLC stimulation, induced TRPC1 channel activity which was also inhibited by an anti-PIP~2~ antibody. Moreover OAG did not evoke TRPC1 channel activity in cells pre-treated with high concentrations of wortmannin, which depleted tissue PIP~2~ levels. These electrophysiological data are consistent with a pathway in which ET~B~ receptors are coupled to PI-PLC, which generates DAG and subsequently induces PIP~2~-mediated activation of TRPC1 channels.

Application of exogenous PIP~2~ evoked TRPC1 channel currents and co-immunoprecipitation studies showed that PIP~2~ co-associated with TRPC1 proteins in resting and ET-1-stimulated tissues. This finding is similar to a previous study in rabbit portal vein myocytes in which it was concluded that PIP~2~ is tethered to TRPC1 proteins at rest but PKC-mediated phosphorylation of TRPC1 proteins was necessary to cause channel opening ([@b34], see [@b23] for more detail). We propose that a similar mechanism may be important for ET~B~ receptor stimulation in coronary artery myocytes.

Therefore the present work shows that both PIP~2~ and PIP~3~ can activate TRPC1 channels in coronary artery myocytes and our evidence is that PIP~3~ is obligatory for ET~A~ receptor-mediated stimulation of TRPC1 channels whereas PIP~2~ is necessary for ET~B~ receptor-mediated activation of the same ion channel.

An interesting observation is that ET~A~ and ET~B~ receptor-mediated TRPC1 channel activity is not additive and that antagonism of both ET~A~ and ET~B~ receptors is required to block ET-1-induced activation of TRPC1 channels. This suggests that both pathways were equally effective in activating TRPC1 channels with the conditions used in our experiments and may indicate a safeguard mechanism for channel activation. Moreover these data indicate how two receptor subtypes converge onto the same TRPC1 channel utilising different transduction pathways.

Role of PKC in activation mechanism of native TRPC1 channels by ET~A~ and ET~B~ receptor stimulation
----------------------------------------------------------------------------------------------------

Stimulation of TRPC1 activity by both ET~A~ and ET~B~ receptors in coronary artery myocytes was almost abolished by the PKC inhibitor chelerythrine. In addition, the responses of PIP~3~ and PIP~2~, the proposed mediators of respectively ET~A~ and ET~B~ receptors stimulation, were also blocked by chelerythrine. Therefore it is evident that PKC plays a central role in the activation mechanism of TRPC1 channels by ET-1. Previously we demonstrated in rabbit portal vein myocytes that TRPC1 channel activation by the sarcoplasmic reticulum Ca^2+^-ATPase inhibitor cyclopiazonic acid (CPA), phorbol 12,13-dibutyrate (PDBu), a PKC stimulant, and PIP~2~ was associated with phosphorylation of TRPC1 proteins which was inhibited by chelerythrine ([@b34]). [@b1] also demonstrated that PKC-evoked phosphorylation of expressed TRPC1 channels regulated store-operated Ca^2+^ entry in cultured endothelial cells. Importantly, the present work adds significant support for the postulated activation mechanism of TRPC1 channels (see [@b23] for fully explanation) by showing that PIP~3~, another notable endogenous phospholipid, also acts as a stimulatory ligand of TRPC1 channels and requires a PKC-dependent process which is likely to involve phosphorylation of TRPC1 subunits. In future experiments it will be interesting to investigate the molecular basis of PIP~3~/PIP~2~-mediated activation mechanisms of native TRPC1 channels using expressed heterotetrameric channels involving TRPC1 subunits.

It has been shown that PIP~3~ also activates some PKC isoforms *in vitro* ([@b27]). Therefore on ET~A~ receptor stimulation production of PIP~3~ is likely both to activate PKC and also to activate TRPC1 channels, which leads to opening of channels through a positive feedback process in which increased PKC-dependent phosphorylation of TRPC1 proteins results in greater PIP~3~-mediated channel activity. A similar transduction mechanism has been proposed to link expressed M~2~ muscarinic receptors to an endogenous chloride channel in *Xenopus* oocytes ([@b42]).

The observation that bath application of ET-1 evoked channel activity recorded in a cell-attached patch suggests that important signalling molecule(s) outlined above translocate from receptors stimulated outside the patch to ion channels underneath the pipette tip. A characteristic of native TRPC channels is that once these signalling pathways are activated by bath applied agonists in the cell-attached configuration channel activity persists after excision into the inside-out configuration. In this configuration there is no agonist present and it is possible that processes that normally inhibit channel activity are lost (e.g. cytosolic factors) when the membrane patch is excised.

Multiple transduction mechanisms and TRPC channels in vascular smooth muscle
----------------------------------------------------------------------------

In cell lines, receptor-mediated activation of expressed TRPC channels is generally shown to be via stimulation of G~αq/11~ and activation of PI-PLC (e.g. see [@b16]), but in vascular smooth muscle more diverse signalling pathways are involved. Therefore α~1~-adrenoceptors and angiotensin II (Ang II) receptors are coupled to TRPC6 channels via PI-PLC in respectively rabbit portal vein and mesenteric artery myocytes ([@b17]; [@b18]; [@b32]). In contrast constitutive TRPC3 channels in rabbit ear artery myocytes are coupled to G~αi/o~ proteins linked PC-PLD-induced production of DAG ([@b4]; [@b5], [@b6]). The present work adds yet another signalling cascade for TRPC channels in which ET~A~ receptor stimulation causes PI-3-kinase-mediated production of PIP~3~ to activate TRPC1 channels.

Agents that deplete intracellular Ca^2+^ stores also stimulate TRPC1 channel activity and therefore these channels are often termed store-operated channels (SOCs). The present results with ET-1 and previous work with noradrenaline in portal vein ([@b2]) and Ang II in mesenteric artery ([@b32]) indicate that membrane-delimited lipid pathways induce TRPC1 channel activity in isolated patches. Consequently TRPC1 channels behave more as receptor-operated channels than as SOCs according to their strict definition.

Phospholipids and TRPC channels
-------------------------------

There is increasing evidence that phospholipids regulate transient receptor potential channels including TRPC channel subtypes in native vascular myocytes and in expression systems ([@b16]; [@b31]; [@b41]; [@b28]; [@b23]). Endogenous PIP~2~ inhibits the excitatory effects of DAG on TRPC6 in mesenteric artery myocytes ([@b7]) and also inositol 1,4,5-trisphosphate potentiates the excitatory effects of DAG on both native TRPC6 and TRPC1 channels in rabbit portal vein myocytes ([@b3]; [@b25]; [@b33]). PIP~2~ has also been shown to have complex actions on expressed TRPC conductances with this phospholipid increasing TRPC3, TRPC6 and TRPC7 channel activity ([@b24]), inhibiting TRPC4 whole-cell currents ([@b29]) and having both excitatory and inhibitory effects on TRPC5 channel activity ([@b39]). There is little information on the action on PIP~3~ on TRPC channels although this phospholipid has been shown to increase expressed TRPC6-mediated Ca^2+^ entry in HEK293 cells recorded with a Ca^2+^-sensitive dye ([@b38]). However the present data provide the first direct evidence that PIP~3~ activates native TRPC channels in any cell type.

Conclusion
----------

This study demonstrates that ET-1 activates native TRPC1 channels in rabbit coronary artery myocytes using two distinct phospholipid signalling pathways. The data show that PIP~3~ and PIP~2~ mediate the responses to respectively ET~A~ and ET~B~ receptor stimulation and facilitate opening of native TRPC1 channels. This is the first demonstration that PIP~3~ activates native TRPC1 channels in vascular smooth muscle.

AgP

:   antigenic peptide

CPA

:   cyclopiazonic acid

DAG

:   diacylglycerol

ET-1

:   endothelin-1

OAG

:   1-oleoyl-2-acetyl-*sn*-glycerol

PI-3-kinase

:   phosphoinositol-3-kinase

PIP~2~

:   phosphatidylinositol-4,5-bisphosphate

phosphatidylinositol-3,4,5-trisphosphate

PLC

:   phosphoslipase C

PKC

:   protein kinase C

TRPC

:   canonical transient receptor potential
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